STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] Arbutus Biopharma Corporation SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Two Seas Capital and affiliated reporting persons disclosed beneficial ownership of 10,443,317 common shares of Arbutus Biopharma (symbol: ABUS), representing 5.4% of the outstanding class as of June 30, 2025. The stake is held in two funds — 7,472,841 shares in the Two Seas Global (Master) Fund and 2,970,476 shares in the Two Seas LNP Opportunities (Master) Fund — and the reporting persons state they have sole voting and sole dispositive power over all reported shares. The filing includes a certification that the securities are held in the ordinary course of business and were not acquired with the purpose of changing or influencing control of the issuer. The disclosure references a total share count of 191,641,511 common shares used to calculate the percentage.

Positive
  • Material disclosure: Reporting persons publicly disclose a 5.4% stake (10,443,317 shares) in Arbutus, meeting SEC reporting thresholds.
  • Clear voting/dispositive authority: The filing states sole voting and sole dispositive power over all reported shares.
  • Detailed allocation: Holdings are itemized between two funds: 7,472,841 and 2,970,476 shares, improving transparency.
  • Certification of ordinary-course holdings: Item 10 affirms the securities are held in the ordinary course and not to change or influence control.
Negative
  • None.

Insights

TL;DR Two Seas reports a material 5.4% position (10.44M shares) in Arbutus with sole voting/dispositive power, certified as ordinary-course holdings.

The filing shows a clear beneficial position of 10,443,317 shares, equal to 5.4% of Arbutus' 191,641,511 outstanding shares. Holdings are allocated between two funds (7,472,841 and 2,970,476 shares), and the reporting persons assert sole voting and dispositive authority. The statement under Item 10 that the securities are held in the ordinary course and not for control purposes frames this as a disclosure of material ownership rather than an attempt to influence governance. For investors, this is notable ownership-level information but contains no operational or strategic commitments.

TL;DR A >5% beneficial stake with sole voting/dispositive power is material for governance disclosure but is presented as non-control, ordinary-course ownership.

The report documents that Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi collectively hold 10,443,317 shares (5.4%), and explicitly state sole voting and dispositive power over those shares. Item 10 provides a certification that the shares were not acquired to change or influence control, which distinguishes this Schedule 13G-style disclosure from an activist 13D filing. The filing supplies precise holding amounts and the issuer share base used for the percentage calculation, allowing transparent assessment of ownership concentration.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Two Seas Capital LP
Signature:/s/ Sina Toussi
Name/Title:Sina Toussi / Managing Member of Two Seas Capital GP LLC, its General Partner
Date:08/13/2025
Two Seas Capital GP LLC
Signature:/s/ Sina Toussi
Name/Title:Sina Toussi / Managing Member
Date:08/13/2025
Sina Toussi
Signature:/s/ Sina Toussi
Name/Title:Sina Toussi
Date:08/13/2025

FAQ

Who filed the Schedule 13G for Arbutus Biopharma (ABUS)?

The statement was filed on behalf of Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi.

How many Arbutus (ABUS) shares does Two Seas Capital report owning?

The reporting persons disclose beneficial ownership of 10,443,317 common shares of Arbutus.

What percentage of ABUS does the reported holding represent?

The disclosed position represents 5.4% of the class, based on 191,641,511 shares outstanding.

How are the reported shares allocated between funds?

The filing states 7,472,841 shares are held by the Two Seas Global (Master) Fund and 2,970,476 shares by the Two Seas LNP Opportunities (Master) Fund.

What voting or dispositive power do the reporting persons claim over the shares?

The reporting persons claim sole voting power and sole dispositive power over all 10,443,317 shares reported.

Were the shares acquired to change or influence control of Arbutus?

Item 10 certifies that the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
Arbutus Biopharm

NASDAQ:ABUS

ABUS Rankings

ABUS Latest News

ABUS Latest SEC Filings

ABUS Stock Data

874.15M
150.34M
21.87%
62.58%
5.5%
Biotechnology
Pharmaceutical Preparations
Link
United States
WARMINSTER